Trial Profile
A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SHR 0534 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 01 Mar 2021 Results assessing safety and tolerability published in the Xenobiotica
- 27 Apr 2016 New trial record